Menopause — Med2Date

📋 Key Information Summary

📋

Definition: Menopause is the permanent cessation of menstruation due to ovarian follicular depletion, confirmed retrospectively after 12 months of amenorrhoea.
Stages: The menopausal transition (perimenopause) is characterised by irregular cycles and vasomotor symptoms, preceding the final menstrual period.
Key Symptoms: Vasomotor symptoms (hot flushes, night sweats), urogenital atrophy, mood changes, sleep disturbance, and musculoskeletal pain are common.
Long-term Risks: Oestrogen deficiency accelerates bone loss (osteoporosis) and is associated with an adverse cardiovascular risk profile.
Diagnosis: Primarily clinical in women >45 years. Investigations (FSH) are reserved for younger women or atypical presentations.
HRT First-line: Menopausal Hormone Therapy (MHT) is the most effective treatment for vasomotor and urogenital symptoms. Transdermal oestrogen is preferred for lower VTE risk.
HRT Risks: Benefits generally outweigh risks for symptomatic women <60 years or within 10 years of menopause. Individual risk assessment for VTE, stroke, and breast cancer is mandatory.
Non-hormonal Options: SSRIs/SNRIs (e.g., venlafaxine), gabapentin, and cognitive behavioural therapy are alternatives for VMS when MHT is contraindicated.
Urogenital Syndrome: Vulvovaginal atrophy requires specific low-dose vaginal oestrogen therapy, which is safe and effective long-term.
Bone Health: Baseline DEXA scan is recommended at menopause for women with risk factors. Adequate calcium and vitamin D intake are essential.
Special Populations: Premature ovarian insufficiency (POI) requires hormone therapy until at least age 50. Management in ATSI women must be culturally safe and address access barriers.
Review: MHT requires annual review of ongoing need, dose, and route, with consideration of discontinuation after 5 years unless symptoms persist.

🎧 Audio Brief

Clinical Guidelines for Menopause Management

A short clinical audio briefing generated from this article — perfect for the commute or ward round.

Menopause clinical infographic — pathophysiology, clinical clues, diagnosis, imaging, and management — Tap or click image to enlarge — Menopause: pathophysiology, clinical clues, diagnosis, imaging, and management.

Introduction & Australian Epidemiology

Menopause is the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. It is a physiological milestone defined retrospectively after 12 consecutive months of amenorrhoea in the absence of other pathological or physiological causes. The average age of natural menopause in Australia is 51-52 years.

The transition phase preceding menopause, known as perimenopause or the menopausal transition, can last for several years and is marked by irregular menstrual cycles and the onset of vasomotor symptoms (VMS). Approximately 80% of Australian women experience VMS, with 20-30% seeking medical treatment for moderate to severe symptoms. The demographic impact is substantial; with an ageing population, a significant proportion of the female population is either in the menopausal transition or post-menopausal.

The decline in oestradiol has widespread systemic effects, impacting cardiovascular, musculoskeletal, neurological, and urogenital health. Management aims to alleviate symptoms, improve quality of life, and mitigate long-term health risks, requiring an individualised approach based on symptom burden, personal preferences, and risk factor profile.

Physiology & Perimenopause

Menopause results from the exhaustion of the ovarian follicular pool. The reproductive years are characterised by cyclical follicular development, ovulation, and corpus luteum formation, driven by the hypothalamic-pituitary-ovarian (HPO) axis.

Stages of Reproductive Aging (STRAW+10 Criteria)

Stage	Name	Key Characteristics
-5 to -3	Reproductive	Regular menstrual cycles
-2	Early Menopausal Transition	Persistent ≥7 day difference in cycle length
-1	Late Menopausal Transition	≥60 days of amenorrhoea; FSH rises
+1a to +1c	Postmenopause	Permanent amenorrhoea; oestradiol low

During perimenopause, cycles become irregular due to fluctuating and often high oestradiol levels with low progesterone, creating a relatively hyper-oestrogenic, anovulatory state. This phase is associated with heavy menstrual bleeding in some women. Ultimately, oestradiol levels decline to a consistently low baseline.

Clinical Features & Complications

Vasomotor Symptoms (VMS)

Hot flushes and night sweats are the hallmark symptoms, affecting 75-80% of women. They are caused by dysfunction in the thermoregulatory nucleus of the hypothalamus due to oestrogen withdrawal.

Genitourinary Syndrome of Menopause (GSM)

Previously termed vulvovaginal atrophy, GSM encompasses vaginal dryness, irritation, dyspareunia, urinary urgency, and recurrent UTIs. It is progressive and does not spontaneously remit.

Long-Term Complications

Musculoskeletal

Osteoporosis & Arthralgia

Oestrogen deficiency accelerates bone resorption. Joint pain (arthralgia) is a common symptom. Fracture risk increases significantly.

Screening: DEXA scan if risk factors present

Cardiovascular

Increased CVD Risk

Loss of oestrogen's cardioprotective effects leads to an adverse lipid profile, increased central adiposity, and endothelial dysfunction.

Management: Address traditional CVD risk factors aggressively

Psychological

Mood & Cognitive Changes

Increased risk of depressed mood, anxiety, and subjective cognitive decline ("brain fog"), though dementia risk is complex.

Evaluation: Screen for perimenopausal depression

Investigations

Diagnosis is clinical for women over 45 with typical symptoms and menstrual cycle changes. Investigations are not routinely required but can be useful in specific contexts.

MBS 66800

Follicle-Stimulating Hormone (FSH)

Elevated levels (>25 IU/L) confirm ovarian insufficiency. Not reliable in women using combined oral contraception. Most useful to diagnose Premature Ovarian Insufficiency (POI) in women <40.

MBS 66684

Thyroid Function Tests (TSH)

Rule out thyroid dysfunction (hypothyroidism/hyperthyroidism) as a cause of similar symptoms (e.g., fatigue, flushes, mood changes).

MBS 66830

Oestradiol (E2)

A consistently low level (<100 pmol/L) supports post-menopausal status, but levels fluctuate greatly in perimenopause. Not diagnostic alone.

Consider

Full Blood Examination (FBE)

If heavy menstrual bleeding (HMB) is a feature, to assess for iron deficiency anaemia.

Specialist

Dual-Energy X-ray Absorptiometry (DEXA)

For bone mineral density assessment. PBS-subsidised for post-menopausal women with specific risk factors (e.g., prior fragility fracture, long-term corticosteroids).

⚠️

Important: Pregnancy must be excluded in perimenopausal women presenting with amenorrhoea or irregular bleeding, especially before commencing MHT. A urine or serum β-hCG is prudent.

Hormone Replacement Therapy (HRT) / Menopausal Hormone Therapy (MHT)

MHT remains the most effective treatment for vasomotor symptoms and urogenital atrophy. Therapy should be individualised, using the lowest effective dose for the shortest duration required, but with recognition that many women benefit from longer-term use for persistent symptoms and quality of life.

🛑

Contraindications (Absolute): Unexplained vaginal bleeding, active liver disease, history of or current VTE (especially with oral oestrogen), history of oestrogen-sensitive cancer (e.g., breast cancer), active arterial thromboembolic disease.

Systemic MHT for Vasomotor Symptoms

💊

Oestradiol (Transdermal)

Estraderm® MX, Estradot®, Climara® · Oestrogen patch/gel

Adult dose 25-100 mcg/day patch (changed 1-2x weekly) or 0.5-1.5 mg/day gel

Key advantage Lower VTE risk than oral; first-line per guidelines.

PBS status ✔ PBS General Benefit

💊

Progesterone (for endometrial protection)

Prometrium®, Provera® · Oral micronised progesterone or synthetic progestogen

Adult dose Prometrium® 100-200 mg daily (cyclical or continuous) or MPA 2.5-5 mg daily

Critical note Mandatory in women with an intact uterus to prevent endometrial hyperplasia.

PBS status ✔ PBS General Benefit

Non-Hormonal Prescribing for VMS

💊

Venlafaxine

Efexor XR® · SNRI

Adult dose 37.5-75 mg daily; start low and titrate

PBS status ✔ PBS General Benefit (for depression - VMS use is off-PBS)

💊

Gabapentin

Neurontin®

Adult dose 300 mg TDS; max 900 mg/day

PBS status ✔ PBS General Benefit (for neuropathic pain - VMS use is off-PBS)

Local Oestrogen for GSM

💊

Oestradiol (Vaginal)

Vagifem® (tablets), Ovestin® (cream, includes estriol)

Adult dose Vagifem: 10 mcg tablet vaginally, twice weekly. Ovestin: 0.5mg/g cream, 0.5g 2-3x/week.

Key point Minimal systemic absorption. Safe for long-term use. Progesterone co-therapy not required.

PBS status ✔ PBS General Benefit

Special Populations

🤰 Pregnancy & Contraception

Women are potentially fertile until 2 years after final period if <50, or 1 year if >50. Contraception is required.

MHT is not a contraceptive. A levonorgestrel IUD (Mirena®) can provide endometrial protection within MHT and contraception.

👶 Premature Ovarian Insufficiency (POI)

Menopause before age 40. Requires hormone replacement (MHT or COCP) at least until average age of natural menopause (~51) to protect bone and cardiovascular health.

Higher dose requirements than standard MHT often needed (e.g., 100mcg transdermal oestradiol).

🎗️ Breast Cancer Survivors

MHT is generally contraindicated. Non-hormonal therapies (SSRIs, gabapentin) are first-line for VMS.

Low-dose vaginal oestrogen for GSM may be considered after discussion with oncologist, especially if on aromatase inhibitors.

🩸 Renal/Hepatic Impairment

Transdermal oestrogen preferred (avoids first-pass hepatic metabolism).

Use with caution in severe renal or hepatic disease; monitor closely.

Aboriginal and Torres Strait Islander Health

Epidemiology & Access

ATSI women may experience menopause earlier and have a higher prevalence of chronic conditions (diabetes, CVD) that complicate management. Significant barriers to specialist care exist in remote and very remote communities.

Cultural Considerations

Discussions around menopause, sexual health, and GSM require culturally safe practice. Using Aboriginal Health Workers or Liaison Officers as intermediaries can improve engagement and understanding.

Clinical Priorities

Focus on holistic assessment. Aggressive management of modifiable cardiovascular and osteoporosis risk factors is crucial. Ensure access to PBS-subsidised MHT and vaginal oestrogen. Support with bone density screening (DEXA) may require coordination with visiting services.

Resource

Refer to the Australian Indigenous HealthInfoNet for relevant resources and frameworks. Management should align with RACGP guidelines for preventive care in ATSI populations.

📚 References

1. The Royal Australian College of General Practitioners (RACGP). Management of menopause. East Melbourne, Vic: RACGP; 2022.
2. Australasian Menopause Society (AMS). Menopause and midlife health: Information for women. 2023. Available from: [https://www.menopause.org.au].
3. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-68.
4. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013;(12):CD001395.
5. The North American Menopause Society (NAMS). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
6. Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50.
7. Australian Institute of Health and Welfare (AIHW). Menopause in Australia. Canberra: AIHW; 2023.
8. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1(1):CD004143.
9. Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-22.
10. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). Management of the menopause. C-Obs 47. 2020.
11. National Aboriginal Community Controlled Health Organisation (NACCHO). Position statement: Aboriginal and Torres Strait Islander health. 2023.
12. The Australian Menopause Society (AMS). Consensus statement: The role of MHT in the management of menopause. 2024.